Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT00100685
First received: January 4, 2005
Last updated: April 25, 2012
Last verified: April 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2007
  Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)